David Kardatzke

7.5k total citations · 2 hit papers
25 papers, 5.2k citations indexed

About

David Kardatzke is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Surgery. According to data from OpenAlex, David Kardatzke has authored 25 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 7 papers in Epidemiology and 4 papers in Surgery. Recurrent topics in David Kardatzke's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Pneumonia and Respiratory Infections (5 papers) and Respiratory and Cough-Related Research (4 papers). David Kardatzke is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12 papers), Pneumonia and Respiratory Infections (5 papers) and Respiratory and Cough-Related Research (4 papers). David Kardatzke collaborates with scholars based in United States, Australia and Brazil. David Kardatzke's co-authors include Williamson Z. Bradford, Marilyn K. Glassberg, Paul W. Noble, Lisa Lancaster, Talmadge E. King, Steven A. Sahn, Ian Glaspole, Steven D. Nathan, Jeffrey J. Swigris and David J. Lederer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and CHEST Journal.

In The Last Decade

David Kardatzke

25 papers receiving 5.0k citations

Hit Papers

A Phase 3 Trial of Pirfenidone in Patients with Idiopathi... 2011 2026 2016 2021 2014 2011 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    2014 2.6k citations Talmadge E. King, Williamson Z. Bradford et al. New England Journal of Medicine profile →
  2. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
    2011 1.5k citations Paul W. Noble, Carlo Albera et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Kardatzke United States 14 4.2k 1.4k 578 569 490 25 5.2k
Yuzo Suzuki Japan 33 1.9k 0.4× 1.0k 0.8× 690 1.2× 349 0.6× 505 1.0× 189 3.9k
Kurt Hong United States 17 1.2k 0.3× 784 0.6× 295 0.5× 111 0.2× 524 1.1× 36 3.1k
Shahzad Ahmad United States 23 2.2k 0.5× 794 0.6× 266 0.5× 120 0.2× 339 0.7× 77 3.2k
Dirk Skowasch Germany 28 1.6k 0.4× 898 0.6× 357 0.6× 114 0.2× 415 0.8× 215 3.0k
James Witter United States 21 1.7k 0.4× 743 0.5× 128 0.2× 1.4k 2.5× 325 0.7× 29 3.2k
Josep M. Grau Spain 32 1.9k 0.5× 297 0.2× 378 0.7× 1.3k 2.3× 1.0k 2.1× 71 3.8k
Robert R. Lorenz United States 35 1.3k 0.3× 1.3k 0.9× 311 0.5× 103 0.2× 1.3k 2.7× 186 4.0k
Peter B. Licht Denmark 36 1.6k 0.4× 377 0.3× 146 0.3× 160 0.3× 1.4k 2.8× 130 4.4k
Erika Gromnica‐Ihle Germany 32 860 0.2× 412 0.3× 363 0.6× 2.9k 5.1× 379 0.8× 87 4.7k
John L. Faul United States 27 1.1k 0.3× 1.1k 0.8× 216 0.4× 82 0.1× 722 1.5× 69 2.9k

Countries citing papers authored by David Kardatzke

Since Specialization
Citations

This map shows the geographic impact of David Kardatzke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kardatzke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kardatzke more than expected).

Fields of papers citing papers by David Kardatzke

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kardatzke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kardatzke. The network helps show where David Kardatzke may publish in the future.

Co-authorship network of co-authors of David Kardatzke

This figure shows the co-authorship network connecting the top 25 collaborators of David Kardatzke. A scholar is included among the top collaborators of David Kardatzke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kardatzke. David Kardatzke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maher, Toby M., Ulrich Costabel, Marilyn K. Glassberg, et al.. (2020). Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 57(2). 1902442–1902442. 51 indexed citations
2.
Nathan, Steven D., Carlo Albera, Williamson Z. Bradford, et al.. (2016). Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. The Lancet Respiratory Medicine. 5(1). 33–41. 237 indexed citations
3.
Lederer, David J., Williamson Z. Bradford, Elizabeth A. Fagan, et al.. (2015). Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. CHEST Journal. 148(1). 196–201. 30 indexed citations
4.
5.
King, Talmadge E., Williamson Z. Bradford, Elizabeth A. Fagan, et al.. (2014). A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 370(22). 2083–2092. 2606 indexed citations breakdown →
6.
King, Talmadge E., Williamson Z. Bradford, Elizabeth Fagan, et al.. (2014). Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP). 44. 4629. 1 indexed citations
7.
Noble, Paul W., Carlo Albera, Williamson Z. Bradford, et al.. (2011). Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. The Lancet. 377(9779). 1760–1769. 1478 indexed citations breakdown →
8.
9.
10.
11.
Wallace, Arthur W., et al.. (2004). Effect of Clonidine on Cardiovascular Morbidity and Mortality after Noncardiac Surgery. Anesthesiology. 101(2). 284–293. 146 indexed citations
12.
Garwood, Susan, et al.. (2004). Adverse Gastrointestinal Complications After Cardiopulmonary Bypass: Can Outcome Be Predicted from Preoperative Risk Factors?. Anesthesia & Analgesia. 98(6). 1610–1617. 50 indexed citations
13.
Swanson, James M., S.B. Wigal, Marc Lerner, et al.. (1998). Evaluation of individual subjects in the analog classroom setting: I. Examples of graphical and statistical procedures for within-subject ranking of responses to different delivery patterns of methylphenidate.. PubMed. 34(4). 825–32. 29 indexed citations
14.
Kammen, Daniël P. van, Joseph P. McEvoy, Steven D. Targum, David Kardatzke, & Terri Sebree. (1996). A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology. 124(1-2). 168–175. 135 indexed citations
15.
Bluestone, Charles D., et al.. (1994). Identification of Middle Ear Effusion by Aural Acoustic Admittance and Otoscopy. Ear and Hearing. 15(4). 310–323. 90 indexed citations
16.
Mandel, Ellen M., David Kardatzke, Charles D. Bluestone, & Howard E. Rockette. (1993). A comparative evaluation of cefaclor and amoxicillin in the treatment of acute otitis media. The Pediatric Infectious Disease Journal. 12(9). 726–732. 8 indexed citations
17.
Nozza, Robert J., et al.. (1992). Towards the Validation of Aural Acoustic. Ear and Hearing. 13(6). 442–453. 71 indexed citations
18.
Chan, Kenny H., William J. Doyle, J. Douglas Swarts, et al.. (1992). Experimental Otitis Media Evaluated by Magnetic Resonance Imaging: An in Vivo Model. Annals of Otology Rhinology & Laryngology. 101(3). 248–254. 10 indexed citations
19.
Doyle, William J., David P. Skoner, Philip Fireman, et al.. (1992). Rhinovirus 39 infection in allergic and nonallergic subjects. Journal of Allergy and Clinical Immunology. 89(5). 968–978. 55 indexed citations
20.
Chan, Kenny H., et al.. (1988). Efficacy of a New Macrolide (Azithromycin) For Acute Otitis Media in the Chinchilla Model. Archives of Otolaryngology - Head and Neck Surgery. 114(11). 1266–1269. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuzo Suzuki Breakdown of academic impact, for papers by Kurt Hong Breakdown of academic impact, for papers by Shahzad Ahmad Breakdown of academic impact, for papers by Dirk Skowasch Breakdown of academic impact, for papers by James Witter Breakdown of academic impact, for papers by Josep M. Grau Breakdown of academic impact, for papers by Robert R. Lorenz Breakdown of academic impact, for papers by Peter B. Licht Breakdown of academic impact, for papers by Erika Gromnica‐Ihle Breakdown of academic impact, for papers by John L. Faul
Rankless by CCL
2026